
X
FDA rejects Amgen/UCB osteoporosis drug
https://pharmaphorum.com/news/fda-rejects-amgenucb-osteoporisis-drug/
Sales of Protelos hit by safety restrictions.
Competitor to Amgen’s Epogen also moves closer to market
Antibody-drug conjugate with FDA gets six-month review.
But romosozumab missed secondary endpoint of non-vertebral fractures
Move boosts Amgen and UCB, which are developing a rival.
The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen